MAP2K7 and neoplasm: The potential clinical utility of immune targeting EGFR-positive CM cells even before or concomitantly to targeted therapy could find additional rationale from a recent paper showing the presence of rare cell populations variants, marked by surface EGFR-expression, that are poised to resistance to targeted therapies and which could contribute to tumor outgrowth upon BRAF/MEK inhibition (70).